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Very small embryonic-like stem cells (VSELs) represent a real
challenge in stem cell biology: recent pros and cons in the midst
of a lively debate
MZ Ratajczak1, E Zuba-Surma2, W Wojakowski3, M Suszynska1, K Mierzejewska4, R Liu1, J Ratajczak1,4, DM Shin5 and M Kucia1,4
The concept that adult tissue, including bone marrow (BM), contains early-development cells with broader differentiation potential
has again been recently challenged. In response, we would like to review the accumulated evidence from several independent
laboratories that adult tissues, including BM, harbor a population of very rare stem cells that may cross germ layers in their
differentiation potential. Thus, the BM stem cell compartment hierarchy needs to be revisited. These dormant, early-development cells
that our group described as very small embryonic-like stem cells (VSELs) most likely overlap with similar populations of stem cells that
have been identified in adult tissues by other investigators as the result of various experimental strategies and have been given
various names. As reported, murine VSELs have some pluripotent stem cell characteristics. Moreover, they display several epiblast/
germline markers that suggest their embryonic origin and developmental deposition in adult BM. Moreover, at the molecular level,
changes in expression of parentally imprinted genes (for example, Igf2–H19) and resistance to insulin/insulin-like growth factor
signaling (IIS) regulates their quiescent state in adult tissues. In several emergency situations related to organ damage, VSELs can be
activated and mobilized into peripheral blood, and in appropriate animal models they contribute to tissue organ/regeneration.
Interestingly, their number correlates with lifespan in mice, and they may also be involved in some malignancies. VSELs have been
successfully isolated in several laboratories; however, some investigators experience problems with their isolation.
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INTRODUCTION
Despite vigorous effort and substantial financial investments, we still
do not have in hand a pluripotent stem cell (PSC) that can be safely
and efficiently employed to regenerate damaged tissues and organs.
Despite a lot of promises, it is difficult even in animal models to
demonstrate, in a reproducible way, that any of the proposed murine
PSCs can rebuild organs, contributing not only to fragments of
parenchyma but also to vessels, nerves and lymphatics. Therefore,
taking into consideration the huge interest and expectations of the
public, we should pursue all possibilities and alternative approaches
to finding such cells, combine our efforts without hostility and
unnecessary competition and leave aside financial interests related to
patents, company stock and funding by private investors or
government agencies. If embryonic stem cells derived by therapeutic
cloning in humans work and are safe, why not try them?1 Similarly, if
induced PSC technology turns out to be effective and safe, why not
try this technology in the clinic?2–5 But why in this competition are
there so many attempts to condemn stem cells isolated from adult
tissues? In fact, because of their safety, stem cells isolated from adult
tissues are the only ones that have so far been tested in clinical
settings. However, we are aware and we have clearly stated several
times that many of the positive effects of adult stem cell therapies
are related to their paracrine effects,6–10 but at the same time, we
cannot exclude other more direct mechanisms.6,11–13
There has been much debate of late challenging the existence
of pluripotent VSELs, these cells which were first isolated in my (MJ
Ratajczak’s) laboratory 10 years ago,14,15 and since have been
experimentally confirmed by several independent groups.16–24
Scientific writers fuelled this dispute by mediating their personal
views through highly respected journals.25,26 Very unfortunately
we found many errors and inaccuracies among their accusations.
In truth these critical comments were recruited from a rather
narrow group of investigators.
These investigators, we fear, sadly had possible vested
financial interests in induced PSC and embryonic stem cell
technology, a very competitive topic. In brief, the small
nucleus of attacking scientists declared that VSELs, like other
stem cells isolated from adult tissues, have no future in
regenerative medicine, and in fact are artifacts. What is
absolutely deplorable in our minds is the claim that clinical trials
based on VSELs were a fake, or at least were not justified.
We cannot help thinking that this was an attack on a grant
allotted to investigators working on VSELs through a peer review
system by the National Institute of Health and Department of
Defense in the United States.
In the wake of these claims and despite the fact that VSELs have
been successfully isolated in several laboratories worldwide, three
recent papers published in open-access journals, PLoS One,27,28
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and the newly created journal Stem Cell Reports,29 reported
unsuccessful attempts to isolate these cells. The unprecedented
furor that has been generated around this topic makes one
wonder what is really going on? We prefer not to comment on the
insinuation that the Vatican is using VSELs to try to control
science.25,26 Some of us are Catholic, like many others, and yes, we
have started this research through curiosity. We are firm believers
in science and we shall once again try to gather all the facts in our
possession to incorporate in this article crucial evidence about the
existence of VSELs.
We will review the most important concepts supporting the
existence of VSELs in adult tissues and address the evidence
against VSELs, and why some have experienced difficulty in
purifying these cells.
FROM STEM CELL PLASTICITY TO VSELS
The concept that adult bone marrow (BM), mobilized peripheral
blood and umbilical cord blood (UCB) harbor early-development
stem cells has been proposed by our team as an alternative to
the plasticity or trans-dedifferentiation theory of hematopoietic
stem cells (HSCs),30,31 which claimed that HSCs can ‘change
their spots’ and give rise to other non-HSCs.32–34 Pursuing an
alternative explanation of stem cell plasticity, we proposed that
adult hematopoietic tissues contain a population of early-
development stem cells,30,31,35 and we focused on isolation and
characterization of these cells at the single-cell level.
In fact, there are numerous reports demonstrating that in adult
murine and human tissues there are rare stem cells that express
early-development markers and are endowed with broader
differentiation potential.36–44 These stem cells have been given
various names, depending on the assays by which they were
identified. In most of these reports, the stem cell that
differentiated into cells from different germ layers has not been
directly identified at the single-cell level. Thus, there was always
the unanswered question: what stem cell is ultimately responsible
for all these multitissue differentiation phenomena? We believe
that many of us studying stem cells residing in adult tissues
that display early-development markers and show broader
differentiation potential are in fact looking at similar,
overlapping populations of stem cells that can be quiescent44
but, if activated, are able to expand into different lineages.
These cells reside at different levels of germ layer/tissue
specification and can be detected if appropriate experimental
tools are employed.
In our work, we assumed from the beginning that the most
primitive stem cells would be small and quiescent and that in BM
they would be more primitive than classical hematopoietic stem
cells or mesenchymal stem cells, positioned at the top of the
developmental hierarchy of these cells. This has, in fact, been
confirmed in recent publications.16,18,45,46 Moreover, in well-
controlled experiments, murine VSELs were demonstrated to give
rise to lung alveolar epithelial cells,17 whereas rat VSELs
differentiated into cardiomyocytes and endothelial cells.47 Finally,
a corresponding population of small embryonic-like stem cells
identified in human and murine ovaries and testes have been
shown by two independent groups to have the potential to give rise
to gametes,19,20,24,48 which be discussed later in this article.
To summarize, the whole concept of the origin and existence of
VSELs in adult tissues is based on the following theses:
 Adult tissues, including murine BM, harbor a population of very
rare stem cells with multiple tissue differentiation potential,
indicating that the hierarchy of the stem cell compartment in
adult tissues and BM needs to be revisited.
 These dormant, early-development cells show several epiblast/
germline markers that suggest their embryonic origin/
deposition and relationship to early epiblast-derived migrating
primordial germ cells (PGCs, Figure 1a). Epigenetic changes in
imprinted genes, such as erasure of the maternal type of
imprinting at differentially methylated regions, which are
specific marks in PGCs to prevent them from undergoing
teratoma formation,49–53 are also responsible for the quiescence
of VSELs in adult tissues. As imprinted genes (for example, those
encoded at the Igf2–H19 locus) are involved in insulin/insulin-
like growth factor signaling (IIS), epigenetically regulated
resistance of VSELs to IIS regulates their quiescent state.54
 However, although these cells can be activated and mobilized
into peripheral blood during several known physiological
emergencies,55–60 they may also be involved in maintaining
the pool of tissue-committed stem cells. The number of VSELs
correlates with lifespan,61–63 and their potential role in
tumorigenesis requires further attention.64,65
Murine BM-purified VSELs possess several in vitro features
expected from PSCs, such as a characteristic morphology in
transmission electron microscopy (a high nuclear/cytoplasmic
ratio with a thin rim of cytoplasm, the presence of euchromatin
and few mitochondria), and express Oct-4 and Nanog at the
mRNA and protein levels,14 which has received further
confirmation by promoter methylation studies showing their
association with histone codes that promote transcription.49
Furthermore, VSELs express bivalent domains at promoters of
developmentally important transcription factors,66 and female
VSELs reactivate the X chromosome.67 In appropriate culture
systems, these cells can also differentiate into cells from different
lineages. Murine VSELs, however, do not form teratomas and do
not complete blastocyst development, which is a key feature of
classical PSCs, such as embryonic stem cells or induced PSCs.
However, this lack of pluripotentiality of murine VSELs should not
be surprising, because early-development stem cells present in
the adult body should be well protected from the risk of teratoma
formation.
THE DEVELOPMENTAL ORIGIN OF VSELS EXPLAINS THE
EPIGENETIC CHANGES REGULATING THE EXPRESSION OF
PATERNALLY IMPRINTED GENES THAT GOVERN THEIR
QUIESCENCE IN ADULT TISSUES
Significant effort has been devoted to characterizing VSELs at the
molecular level in order to determine their developmental origin.
In studies performed on highly purified double-sorted VSELs
isolated under steady-state conditions from murine BM, we
observed that these cells highly express, at the mRNA and/or
protein levels, genes involved in both specification of the epiblast
(for example, Stella, Prdm14, Fragilis, Blimp1, Nanos3 and Dnd1)
and PGCs.68,69 The PGC-specific genes, such as Dppa2, Dppa4 and
Mvh, are characteristic of late-migratory PGCs. The expression
of some of these crucial genes has been confirmed subsequently
by demonstrating the presence of transcriptionally active
promoters.68 Based on the molecular similarity between VSELs
and PGCs, we presented the hypothesis that one of the
mechanisms that keep VSELs quiescent in adult tissues is similar
to the one that governs quiescence of PGCs and is based on
epigenetic modification of paternally imprinted genes (Figure 1b).
Pursuing this hypothesis, we observed that VSELs, like PGCs
migrating during embryonic development, modify the imprinting
of some early-development parentally imprinted gene loci,
including Igf2–H19, which results in their resistance to IIS, and
by modifying imprinting and KCNQ1/p57Kip2 upregulate the
cyclin-dependent kinase inhibitor p57KIP2.49 We also observed
that, in addition to changes in expression of imprinted genes,
VSELs express several miRNAs that attenuate IIS signaling in these
cells (for example, mir681, mir470 and mir669b) as well as
upregulate the expression of p57KIP2 (for example, mir25.1, mir19b
and mir92; M Maj, manuscript in preparation).
VSELs: an update
MZ Ratajczak et al
474
Leukemia (2014) 473 – 484 & 2014 Macmillan Publishers Limited
More importantly, to support a link between PGCs and VSELs as
precursors of long-term repopulating HSCs (LT-HSCs),45,70,71 we
observed that VSELs and HSCs express mRNA for several pituitary
and gonadal hormone receptors as well as highly express Sall4, an
early-development marker shared by germ and hematopoietic
cells.72,73 Finally, in direct in vivo and in vitro experiments, we
confirmed that the quiescent population of BM-residing VSELs, like
HSCs, expands in response to stimulation by androgens (danazol)
and pituitary gonadotropins such as pregnant mare serum
gonadotropin (PMSG), luteinizing hormone (LH), and follicle-
stimulating hormone (FSH). In support of this concept, we
observed that a 10-day administration of all these sex hormones
directly stimulated expansion of VSELs and HSCs in BM, as measured
by an increase in the total number of these cells in BM
(B2–3x) and enhanced 5-bromodeoxyuridine (BrdU) incorporation
(the percentage of quiescent BrdUþSca-1þLinCD45 VSELs
increased from B2% to B15–35%, and the percentage of
BrdUþSca-1þLinCD45þ HSCs increased from 24% to 43–58%)
(K Mierzejewska, manuscript in preparation).
Overall, our 2008 paper demonstrated for the first time that the
quiescent state of the most primitive stem cells in murine BM can
be regulated by epigenetic changes of imprinted genes,49 as seen
Figure 1. The overall concept of a presence of developmental early epiblast/germline-derived stem cells in adult tissues. (a) Retention of
germline potential during ontogenesis. Cells with germline potential are shown in blue. The earliest and the most primitive cell in the
germline is the totipotent zygote. The germline potential is subsequently retained during development in Oct-4þ cells located in the inner
cell mass cells (ICMs) of the developing blastocyst, epiblast stem cells (EPSCs), primordial germ cells (PGCs) and gonocytes in gonads. Epiblast/
germline potential could also be retained in rare early-development small VSELs deposited during development in peripheral tissues as
founders for more differentiated monopotent tissue-committed stem cells. Some of these small cells express Oct-4 (shown in blue). (b) The
cycle of life—from zygote to germ cells. From a developmental and evolutionary point of view, the germline (shown by red arrows) carries
the genome (nuclear and mitochondrial DNA) from one generation to the next, and all somatic cell lines bud out during ontogenesis from the
germline to help germline cells accomplish this mission effectively. The germline potential is established in the fertilized oocyte (zygote) and
subsequently retained in the morula, inner cell mass of the blastocyst (ICM), EPSC, PGCs and mature germline cells (oocytes and sperm). The
first cells that bud out from the germ lineage are trophoectodermal cells, which give rise to the placenta. Subsequently, during gastrulation,
EPSCs are a source of PSCs for all three germ layers (meso-, ecto- and endo-derm) and PGCs. We hypothesize that at this stage some EPSCs
and PGCs are deposited as Oct-4þ VSELs in tissues developing from meso-, ecto- and endo-derm (blue circles). Blue box and yellow arrows
pointing at VSELs indicate mechanism based on epigenetic modification of parentally imprinted genes (for example, at Igf2–H19 and
KCNQ1p57Kip2 loci) that keeps these early-development cells quiescent in adult tissues. A similar mechanism based on erasure of imprinting
also regulates the quiescent state of PGCs.
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in the case of PGCs (Figure 1b). This has been somehow very
recently confirmed in a paper by Venkatraman et al.,74 who found
that most primitive LT-HSCs in murine BM are kept quiescent by
the maternal type of imprinting at the Igf2–H19 locus, which
confers resistance to IIS. As mentioned above, we provided
evidence that VSELs may become specified into LT-HSCs.45,46
RECENT DATA FROM INDEPENDENT LABORATORIES THAT
SUPPORT THE EXISTENCE OF VSELS
As mentioned above, several primitive cells with the character-
istics of pluripotency or multipotency were identified in adult
murine and human BM, UCB and adult solid organs that were
enzymatically processed to get cell suspensions for analysis. Such
cells, more or less depleted of lineage-positive cells,36–39,75–78 were
cultured and expanded in vitro, usually as adherent cell
populations, and if they expanded into cells from different
tissues, they were assigned various operational names such as
multipotent adult stem cells,36 multipotent adult progenitor
cells,39 MIAMI cells,37 multilineage-differentiating stress-
enduring (Muse) cells76,79 or unrestricted somatic stem cells.38
Unfortunately, the phenotype of the most primitive stem cell that
initiated these cultures has never been clearly described. In
addition to assays based on in vitro cultures, other isolation
strategies have also been employed, for example, an interesting
population of small cells (ELH stem cells) isolated from murine BM
by elutriation (E), lineage depletion (L) and the ability to home (H)
to BM has been described, which is able to differentiate into
epithelial cells and HSCs.80–82 Another group reported the
presence of small cells (known as ‘spore-like stem cells’) in adult
mammalian tissues that are able to differentiate into cells from all
germ layers and have been isolated from adult mammalian
tissues.83
Moreover, several recent reports based on fluorescence-
activated cell sorting multiparameter sorting strategies were
published that supported the existence of small, primitive VSELs
and VSEL-like cells in adult tissues (the most important are listed in
Table 1). For example, murine BM-sorted Sca-1þLinCD45
VSELs have been shown to give rise to type 2 pneumocytes,
which produce lung surfactant protein after transplanta-
tion into surfactant-deficient mice.17 Furthermore, small
SSEA1þLinCD45 cells that express Oct4þ sorted from rat
BM gave rise in vivo to cardiomyocytes and endothelial cells in an
experimental model of rodent acute myocardial infarction.47
Furthermore, Sca-1þLinCD45 VSELs cells from murine BM16
or human mobilized peripheral blood18 cells expressing the
SSEA4þCD133þCXCR4þLin and CD45 phenotype and
isolated by fluorescence-activated cell sorting formed murine
and human bones, respectively, when embedded in gelatin
sponges and implanted into immunodeficient mice. This bone-
forming activity exceeded the activity of the other populations of
BM-purified cells that were evaluated using the same assay. Based
on this finding, it has been proposed that these BM- and
mobilized peripheral blood-purified VSELs are at the top of the
hierarchy for the mesenchymal and endothelial lineages.16,18 Cells
similar to BM-derived VSELs have been reported to reside in the
ovarian surface epithelium in postmenopausal ovaries19,48 and
normal testes20 and were able to differentiate into gamete-like
cells. As reported, these gonadal VSELs express nuclear OCT-4A,
whereas the immediate descendants of these cells express
cytoplasmic OCT-4B isoform.19,20
Furthermore, human mobilized peripheral blood VSELs have
been successfully purified by other researchers,18,21 and very small
Oct4þSox2þ cells corresponding to UCB-derived VSELs described
by us15,46 were purified from UCB by other investigators, who
described them as a population of UCB-derived VSELs23,84 or UCB-
derived embryonic-like stem cells.85,86 Interestingly, these cells
were able to differentiate in vitro into neural progenitor cells.85
Finally, a corresponding population of primitive Oct4þ stem cells
that resembles VSELs and was named omnicytes was also
described as circulating in UCB and was capable of migrating
into the maternal circulatory system.87
In addition to the cells listed in Table 1, in a recent report, small
cells with some VSEL markers were also identified in murine
neonatal retina.88 In another study, small non-hematopoietic
lineage-negative (Lin ) cells isolated from adult BM by elutriation
(Fraction 25 or Fr25) were involved in retinal regeneration
following the induction of anterior ischemic optic neuropathy
and optic nerve crush injury in a rodent model.89 In addition, a
similar population of small non-hematopoietic CD45 stem cells
harvested from BM via elutriation was recently shown to
differentiate in vivo into functional insulin-producing cells in
chemically induced diabetic mice.90 Similar small cells isolated by
elutriation were reported in the past to give rise to LT-HSCs.80
Thus, VSELs and VSEL-resembling cells have recently been
purified in several laboratories worldwide, and we can expect that
the coming years will bring more new information regarding their
biology and in vitro and in vivo differentiation potential.
THE ‘DENIERS’, OR WHY SOME INVESTIGATORS WERE
UNSUCCESSFUL IN PURIFYING VSELS
Although VSELs have been successfully isolated in several
independent laboratories, three groups have recently reported
that they were not successful in the isolation of VSELs.27–29 These
events sparked an excessive reaction from some scientific writers,
who published their personal views on the topic using highly
regarded journals as a forum.25,26 We will discuss here from the
scientific point of view the problems that we see with the sorting
strategies employed by the three groups. In our opinion, most of
the difficulties that they encountered27–29 could have been
entirely eliminated or greatly minimized if they had first
contacted us for help and discussion, which is always a good
practice in science.
In the first paper, although Miyanishi et al.29 tried to follow our
isolation protocols for VSEL sorting that were established for mice
BM, they were eventually not successful in VSEL isolation, and
these small cells were somehow lost, either during BM preparation
or in the sorting procedure. This occasionally happens even in our
experienced hands and in the hands of other groups that sort
these very rare cells. Thus, based on our broad experience in VSEL
isolation from several animal species14,61,91–96 and human
specimens,15,46,55,97 we will discuss few main steps in the gating
strategy described by Miyanishi et al.29 that may explain the VSEL
loss and subsequent negative results that this group reported.
First, in our experience, in order to isolate VSELs effectively, a
gate including Lin /Sca-1þ cells should be set up strictly for Lin-
negative objects. Although we understand that the authors’
intention was to enlarge the gate into Lindim objects to increase
VSEL yield, we have found that such a step may in fact greatly
enrich the sorted population in erythroblasts and thus significantly
dilute the VSELs.29 This concern should be taken under
consideration, especially as the authors do not provide detailed
information about their red cell lysis conditions, buffers, cell
washing and the centrifugation of BM cells before VSEL
separation.29 These steps are crucial for successful VSEL isolation
and greatly affect the potential presence of cell debris and
artifacts in BM samples used subsequently for VSEL sorting.
This potential dilution effect could have critically affected
further analytical tests performed on sorted samples,29 such as:
(1) gene expression analysis including Oct-4 (if the VSEL-derived
transcripts are limited, the detected expression could be low or
none) and (2) VSEL functionality in culture (where the initial VSELs
aggregation step is crucial for expansion on both C2C12 and OP-9
cells and the number of VSELs in the seeded material is critical).
Similarly, including CD45int/Lin /Sca-1þ cells in the sorted
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population of CD45 /Lin /Sca-1þ cells (containing, in fact,
VSELs) could result in VSEL dilution and eventually negative
experimental outcomes in any type of functional experiment.29
This might have been avoided if the authors had discussed the
sorting and experimental pitfalls with our groups before
performing their experiments.
Other important steps in sorting and analysis that we would
recommend doing differently than the authors are BM cell
staining with Syto16 and its interpretation.29 The authors use
Syto16 as a dye indicating diploid cells, when in fact it may also
give a signal related to cytoplasmic contents and therefore cannot
be equated with DNA-selective dyes such as 4’,6-diamidino-2-
phenylindole (DAPI) or Hoechst 33342, as indicated by the
manufacturer.98 The manufacturer specifically states: ‘The SYTO
dyes do not act exclusively as nuclear stains in live cells and
should not be equated with DNA-selective compounds such as
DAPI or Hoechst 33 342 which stain nuclei in live animal cells.
Eukaryotic cells incubated with SYTO dyes generally show
cytoplasmic or mitochondrial staining, as well as nuclear
staining’. This was confirmed in recent publication.99 As cell
ploidy is defined by DNA content, clearly SYTO dyes cannot be
used as ploidy markers, and the accuracy of the authors’ ploidy
estimation can be called into question. Despite this obvious
mistake, based on the cell distribution shown in Figure 2C in the
original paper by Miyanishi et al.,29 the authors conclude that
‘VSEL candidates’ consist of the large cells (410 mm) with high
Syto16-related signals (interpreted by the authors as normal, 2n
cells, original Figure 1C29 and shown here as Figure 2a, blue box).
On the contrary, we consider the fraction of smaller cells (FCSlow)
appearing as Sytox16dim cells (originally Figure 1C29 and shown as
Figure 2a in this article, red box) to represent potential VSELs
because of their well-known low cytoplasmic content and greater
resistance to DNA staining, which has been characteristic of these
cells in our experience as well as that of other groups.17,19,96,100
Unfortunately, as Miyanishi et al.29 decided to sort the Syto16bri
cells (which most likely belong to the CD45int subpopulation of
progenitors or erythroblasts in the analyzed material) as ‘VSEL
candidates’, we are not surprised that they were unsuccessful in
isolating VSELs in subsequent steps. Because of this crucial
mistake and their resultant focus on the wrong population, the
authors’ statement ‘This indicated that our VSEL candidates were
the relatively larger cells in the population analyzed, unlike the VSELs
described in previous reports (Kucia et al., 2006; Ratajczak et al.45;
Wojakowski et al.55; Zuba-Surma et al.29,94–96) is not supported by
any evidence.
The Sytox16-related signal may vary between cell populations,
raising questions about its discriminatory role for diploid cell
identification, and this problem is also clearly visible in the
example of the CD45hi/Lin /Sca-1þ cell fraction (located on the
border of the ±10-mm bead size, originally Figure 1C29 and
shown as Figure 2a in this article, green box), which is close to a
half log unit brighter than the majority of FSChi/CD45hi/Lin /Sca-1þ
cells.29 We would like to ask: what does this mean? Does Syto16
indicate that these cells are proliferating, 3n, or are they in fact 2n
and all fractions that the authors interpret as diploid have indeed
a lower DNA content? There must be more controls and more
cautious interpretation in such analysis.
Importantly, staining with DNA-binding dyes or chromosome-
specific probes is not a reliable assay for investigating DNA status,
karyotype and DNA stability of adult stem cells, embryonic stem
cells and also induced PSCs. In our opinion, global genomic
cytogenetic arrays should be performed to confirm normal
genetic status and thus the safety of such cells.
In the second of the ‘con’ papers, Danova-Alt et al.,27 based on
their uncertain-quality fluorescent in situ hybridization staining
with probes directed to only selected chromosomes, concluded
that human UCB-derived CD45 /Lin /CXCR4þ cells (which they
considered wrongly to be VSELs) display a high degree of
aneuploidy. In contrast, we verified the karyotype of human UCB-
derived CD45 /Lin /CD133þ cells (which we in fact consider to
be a VSEL-enriched population) by employing a global genome
cytogenetic array (CytoScan 750K, Affymetrix, Santa Clara, CA,
USA) and definitively confirmed their normal, diploid status, with
neither chromosomal aberrations nor small deletion/insertions in
any gene (E Zuba-Surma, manuscript in press). Importantly, as
mentioned above, Danova-Alt et al.27 focused on the subset of
CD45 /Lin /CXCR4þ UCB cells that we indicated as being least
enriched in VSELs. Based on our data collected within the past few
Table 1. Selected reports from other groups on stem cells that are attributable to VSELs
Cells as originally named in the
paper
Isolation procedure and properties as described in the original paper References
ELH cells Small cells, B5 mm in diameter, isolated by elutriation and FACS sorting or by elutration (E),
lineage depletion (L), and recovered after homing (H) to BM. Give rise to long-term
reconstituting hematopoietic stem cells (LT-HSCs) and epithelial cells.
80–82
Spore-like stem cells Small cells,B5 mm in diameter, isolated from various murine tissues, resistant to freeze/thawing,




Isolated by FACS from murine BM give rise to type II pneumocytes, producing surfactant in lung
alveolar epithelium. Recently, these cells have been confirmed to be VSELs.
17,106
Rat VSELs Isolated by FACS from rat bone marrow as SSEAþ Lin CD45 cells that express Oct-4 and are
endowed with cardiomyogenic and endothelial potential.
47
Human PB-derived VSELs Isolated by FACS as Sca1þLinCD45 from murine BM or as SSEA-4þ CD133þ CXCR4þ Lin
and CD45 from human PB—described as being at the top of the hierarchy for the
mesenchymal lineage. Formed bone fragments in immunodeficient mice.
18,21
Ovarian VSELs Small Oct-4þ SSEAþ cells isolated by FACS from ovarian surface epithelium (OSE) from mice
and humans—precursors of female gametes. Human OSE-derived VSELs were characterized
extensively by gene array for mRNA expression.
19,24,48,107
Testicular VSELs Small Oct-4þ SSEAþ cells identified in murine and human testes—precursors of male gametes 20
Embryonic-like stem cells from
UCB
Small CD45 , CD33 , CD7 , CD235a pluripotent stem cells (2–3mm in diameter)
coexpressing embryonic stem cell markers, including Oct4 and Sox2, and able to differentiate
into neuronal cells.
85,86
UCB VSELs Small Oct-4þ , SSEA-4þ , Nanogþ , Sox-2þ , Rex-1þ , and Tertþ cells isolated from UCB. 15,23,46,84
Omnicytes Small Oct-4þ stem-cells identified in UCB, able to establish fetal–maternal chimerism. 87
Abbreviations: BM, bone marrow; FACS, fluorescence-activated cell sorting; PB, peripheral blood; UCB, umbilical cord blood; VSEL, very small embryonic-like
stem cell.
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years, we clearly suggested that primitive Oct-4þ , SSEA-4þ cells
should be sought within the much rarer fraction of CD45 /Lin /
CD133þ cells.46,97 Unfortunately, Danova-Alt et al.27 disregarded
our recently published results and followed an incorrect
population that we initially isolated 5 years ago and then further
studied.15,46,97 Interestingly, although these authors concluded
that CD45 /Lin cells from UCB essentially lack CD34 and CD133
antigens, these cells are visible even in their histograms (originally
Figure 2B27 and shown as Figure 2b in this article, upper panel),
but the authors inexplicably overlooked the rare objects, including
the VSEL fraction,27 which we clearly indicated in our analysis
done on dot plots (Figure 2b, lower panel). It is clearly apparent
that both CD45 /Lin /CD34þ and CD45 /Lin /CD133þ cells
are present in at least some UCB samples analyzed by Danova-Alt
et al.,27 which are indicated in their original histograms by blue
boxes marking rare objects corresponding to both populations
(Figure 2b, UCB samples 1, 2 and 3). Another important technical
problem is that the authors instead of using for CD133 staining as
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we recommended in our original protocols antibodies against
CD133/1 epitope100 employed not optimized for VSEL isolation an
anti-CD133/2 eiptope antibody (clone: 293C3).
Similarly, in the third of the ‘con’ papers, Szade et al.28 went a
step further and tried to set up an entirely new protocol for
isolation of murine VSELs, discounting our already published
strategies, and eventually sorted a fraction distinctly different from
very small CD45 /Lin /Sca-1þ cells, thus presumably losing the
VSELs during isolation. Using their de novo protocol, these
authors28 made several cardinal mistakes, including: (1) setting
up an enlarged input gate on the forward scatter (FSC) vs side
scatter (SSC) plot that, on one hand, included granulocytes and
apoptotic cells, resulting in enrichment of sorted fractions with
artifacts reflected in further analyses (for example, Annexin V
binding) and, on the other hand, excluded some of the critical
very small objects from further sorting (originally Figure 1A28 and
shown as Figure 2c in this article); (2) losing very small
objects further by cutting them out during gating for ‘singlets’
(originally Figure 1A28 and shown as Figure 2c in this article); (3)
focusing on selection markers that were not proven to be
expressed on VSELs (for example, c-kit); and (4) a selective focus
on some populations and discarding other fractions (containing
potentially VSELs) based on a superficial interpretation of results
such as Annexin V binding.28 For instance, the entire fraction
of CD45 /Lin /Sca-1þ /c-kit /KDR was excluded by the
authors from further sorting because it was deemed ‘apoptotic’
(Figure 228), although it most likely contained not only real
Annexin Vþ /FSClow/SSCdim/hi apoptotic objects, but also VSELs.
Importantly, we have found that healthy normal cells (including
VSELs and HSCs) may bind Annexin V following lysis of red blood
cells because of microvesicle/microparticle release and
posphatydylserine transfer to the membranes of the normal
cells.101 Thus, not all Annexin Vþ objects should be interpreted
as ‘apoptotic’, as these may sometimes represent normal,
functional cells.101
In this regard, even though Miyanishi et al.29 tried to follow our
protocols, we noticed several other flow cytometric concerns
when analyzing the identification and sorting approaches used by
this group.29 For instance, (1) how is it possible that, following red
blood cell lysis, the unfractionated BM cell population does not
contain any Syto16 /Sytox-Blueþ objects, and all events are
shown to be uniformly nucleated or 2n (based on the authors’
Sytox-16 signal interpretation) healthy cells (originally Figure 1C29
and shown as Figure 2a in this article, magenta box), whereas
Syto16 /Sytox-Blueþ objects are shown in subfractions of BM
cells in the same analysis (how much of this analysis is reliable?) or
(2) why are there, in fact, so few cells indicated in the size region
B4–10mm in the original Figure 2C (shown by an arrow in
Figure 1 in this article), although this population was much more
prominent in the analysis shown in the original Figure 1 (shown as
an example here in Figure 2b)—are these vast numbers of cells
resembling VSELs lost following Sytox16 staining or software
compensation? Answers to these and several other questions are
crucial for the academic community to understand the discre-
pancies in proper VSEL identification and sorting encountered by
Miyanishi et al.29 as well as other groups struggling with VSEL
isolation.27,28 We plan to highlight these methodological aspects
in more detail in a separate paper focusing exclusively on
flow cytometric pitfalls and techniques in rare stem cell
characterization, including for VSELs.
Moreover, Miyanishi et al.29 focused particularly on VSEL cell-
size evaluation (originally shown as Figures 1 and 2, and Figure S1
in Miyanishi et al.29). They, for instance, compared the BM cell
distribution with bead standards on different sorting machines
(both Aria (BD Biosciences, San Jose, CA, USA) and MoFlo
(Beckman Coulter, Inc., Brea, CA, USA)) and pointed to visible
discrepancies. We understand that this approach was related to
our sorting protocols suggesting standard-sized beads for gate
set-up. However, when it was already clear from their initial
experiments (shown in the first and second dot plots in the
Figure 2. Flow cytometric concerns regarding VSEL identification and isolation. (a) Miyanishi et al.29 described and subsequently isolated
large-size, Syto16-bright, CD45 /int/Lin /Sca-1þ murine cells as ‘VSEL candidates’ (lower left plot, blue box), whereas in our opinion, a visible
population of smaller, Syto16-dim cells is the most likely VSEL population (lower left plot, red box). Syto16 is not an optimal DNA dye, and its
staining also depends on other intracellular components. It is, for instance, visible in the CD45hi/Lin /Sca-1þ population (lower right plot,
green box), which is almost a half log unit brighter than the majority of FSChi cells (lower right plot, black box). Moreover, we have a general
concern about Sytox-Blue and Sytox16 staining in this study because unfractionated BM cells do not contain any debris or dead cells in such a
sample (upper right plot, magenta box), which are visible within subfractions of these cells. (Dot plots were adopted from a paper by Miyanishi
et al. (Stem Cell Reports; 2013, 1, 1–11; part of Figure 1C)—published in an open-access journal under Creative Commons Attribution-NonCommercial-
No Derivative Works License).29 (b) Danova-Alt et al.,27 in their recent studies focusing on human VSEL isolation, concluded that CD45 /Lin /
CD133þ cells (which we consider in fact to be a population enriched in human VSELs) as well as CD45 /Lin /CD34þ cells do not exist in CB,
whereas such cells are not only found in our samples (lower dot plots, VSELs marked with blue circles), but also in some CB samples (1, 2
and 3) analyzed by Danova-Alt et al. (upper histograms, VSELs marked with blue boxes).27 These rare stem cell populations were overlooked
by Danova-Alt et al.27 because of their visualization on histograms, but are clearly visible when dot plots are used for analysis.97 (Histograms
were adopted from the paper by Danova-Alt et al. (PLOS One; 2012, 7, e34899; part of Figure 2B)—published in an open-access journal under Creative
Commons Attribution License).27 (c) Szade et al.28in their recent studies on VSELs tried to set up a new protocol for murine VSEL isolation. They
were unsuccessful, as they focused on an incorrect fraction and, importantly, lost VSELs during an incorrect gating process.28 A fraction of the
very small objects was lost during: (1) gating on the FSC vs SSC plot (left plot, original gate is shown in black, whereas the suggested classical
gate for VSELs is shown by a red circle) and (2) excluding doublets (right-hand plots, original gates are shown in black, whereas suggested
gates are shown as red boxes, and arrows indicate areas where VSELs were most likely excluded from sorting gates). (Dot plots were adopted
from the paper by Szade et al. (PLOS One; 2013, 8, e63329; part of Figure 1A) published in an open-access journal under Creative Commons Attribution
License).28 (d) Images of selected murine cell populations used for size calculation by imaging cytometry. The left panel shows FlowSight-
derived brightfield images of CD45 /int/Lin /Sca-1þ /Sytox16þ objects that were isolated as ‘VSEL candidates’ by Miyanishi et al..29 Despite
the fact that these cells do not represent the VSEL population described by the Ratajczak group, the quality of images is too poor for accurate
quantitative analyses, including size calculations.29 Importantly, images were collected on the instrument with a low sensitivity that may not
be useful for VSEL characterization (scale indicates 20 mm). (Images were adopted from the paper by Miyanishi et al. (Stem Cell Reports; 2013, 1,
1–11; part of Figure S1C)—published in an open-access journal under Creative Commons Attribution-NonCommercial-No Derivative Works License).29
The middle panel represents size analysis performed by Szade et al.28 using the ImageStream X system. The histogram shows size analysis of
CD45LinSca-1þc-Kit cells, where objects 4-5 mm in size are unfortunately excluded from analysis (as indicated by the orange box),
whereas the images are confusingly derived from the distinct CD45LinSca-1þc-Kitþ cell fraction, which does not represent VSELs.
Importantly, the quality of images is too poor for accurate data analysis. (Data were adopted from the paper by Szade et al. (PLOS One; 2013, 8,
e63329; part of Figure S2)—published in an open-access journal under Creative Commons Attribution License).28 The right panel shows
representative images of murine VSELs (CD45 /Lin /Sca-1þ /7-AADþ cells), HSCs (CD45þ /Lin /Sca-1þ /7-AADþ cells) and platelets
(CD41þ /7-AAD objects) obtained with the ImageStream 100 system and used for VSEL size analysis.96 Importantly, with an optimized
instrument and good-quality images, even objects as small as 2-mm platelets may be visible and quantified by IDEAS software. Cyan areas
show masking used for calculations of cell size by Zuba-Surma et al.96
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original Figure 1)29 that the cell-size measurement based on the
beads employed was not accurate on the particular Aria
instrument used for experiments (as all murine white blood cell
populations appeared erroneously to be 410 mm), the authors
continued the size comparison, which was in fact irrelevant to the
final sorting outcome. On the other hand, the authors should re-
evaluate gating on the instrument they used and VSELs should be
sought in the fraction of objects between 4 and 6 mm or even
between 4 and 8 mm rather than 4 mm, as all objects are shifted to
the upper FSC values when compared with beads (original
Figure 1)29.
Moreover, the authors performed extensive redundant compar-
isons between instruments,29 when it is common flow cytometric
knowledge that the distribution of both synthetic beads and cells
will vary between different instruments (such as, between Aria and
MoFlo, or even between machines within one family) and we
would strongly expect that the BM cells or other objects would
simply ‘come back’ in different locations on FSC vs SSC plots when
compared with the initial instrument employed for sorting of
these objects and other instruments.102 Overall, the authors
concluded, based on their flow cytometric size evaluation, that
classical flow cytometry is not a reliable method for cell-size
analysis and may vary between instruments, with which we
certainly agree. Unfortunately, these size comparisons obviously
did not bring the authors closer to successful VSEL isolation.
Thus, we would like to highlight that in our daily laboratory
practice we employ size-calibrating beads only for the initial
experiments when a new instrument/sorter is being used for VSEL
isolation, to set up the right protocol or when a major recalibration
of the current instrument is performed. There is no ‘magic’ behind
VSEL sorting—just pure biology and the scientifically oriented
mind of a good flow cytometry specialist.
Instead of such kind of ‘prove-of-proof of principle’ experiments,
we suggest focusing on a few important technical hints applicable
to any type of cell sorter that might be used for VSEL sorting:
 Setting a minimal threshold on the instrument.
 Gating for FSC vs SSC dot plots exclusively on lymphocytes
(excluding granulocytes and FSClow/SSChi objects that may
enrich the sorted fraction with different artifacts, apoptotic cells
and so on) with extension of the gate to include FSClow/SSClow
objects, where a clear cutoff from debris is visible (as shown by
our gating strategy in Figure 3).
 Set up a gate enclosing Lin /Sca-1þ cells to avoid erythroblast
contamination. Apoptotic cell and erythrocyte contamination
was reported in the paper by Szade et al.,28 the group that
significantly modified sorting and eventually isolated a murine
BM cell population distinctly different from VSELs. Moreover, the
gating for sorting was performed in an untidy fashion, and very
small cells were lost at different steps28 (Figure 2c). Thus, any
major change in gate set-up that results in VSELs being
unnecessarily mixed with other objects should be carefully
avoided.
 Use dot plots to visualize populations. We generally do not
recommend using histograms for any identification and sorting
of rare fractions of stem cells, including VSELs. Although in our
initial sorting protocols we used histograms visualizing, for
example, CD45 expression for final separation of hematopoietic
and non-hematopoietic cells,14,96 we gradually became aware
that replacing such a histogram with dot plots (for example,
CD45 vs SSC) was much more informative and gave a better
gating set-up (Figure 3). Moreover, we found that rare cells such
as human VSELs have been simply overlooked by other
investigators using histograms showing expression of CD133
and CD34 in CD45 /Lin human UCB samples,27 although
these very rare SCs would be clearly visible in the same samples
and in the same analyses if, for instance, CD133 (or CD34) vs SSC
dot plots are employed97 (Figure 2b).
 Importantly, we also exclude any contour plots from our sorting
and analysis protocols, which were used by Miyanishi et al.,29 as
in our opinion they flatten the view and do not provide
complete information about low cell number clusters
and the single-cell distribution when we focus on isolation of
unique rare objects. We believe that employing contour
plots may also potentially lead to technical problems in
sorting of rare SCs, as the clear borders of subpopulations
are not easily visible.
 Eventually, when gated properly, CD45 /Lin /Sca-1þ cells will
‘come back’ as a homogeneous population of small objects in a
FSC vs SSC dot plot following back gating (Figure 3).
Importantly, our established protocol for murine VSEL isolation
has already been successfully followed and fine-tuned by several
laboratories and investigators, including groups in the United
States, France, India, Japan and Poland,16–19,21,22,88,91,103 a fact that
was not appreciated by any of the investigators (Miyanishi et al.,29
Danova-Alt et al.27 and Szade et al.28) who faced problems with
VSEL sorting.
We have also noticed the interest by Miyanishi et al.29 in VSEL
size measurements by imaging cytometry, a technique in which
we are highly skilled and often use in our studies.94,96,97,104
Unfortunately, in our opinion, FlowSight (Amnis Corporation,
Seattle, WA, USA) is not an optimal choice for morphological
examination of very small objects such as VSELs. Indeed, the
authors should be aware that all of our previous analyses
(which they questioned in their paper29) were performed with a
much more powerful, sophisticated and higher-magnification
ImageStream (Amnis Corporation) system.94,96,97,104 Based on our
observations, although FlowSight is capable of analyzing a
majority of large cells with its single  20 objective and fixed
optical configuration,105 it cannot provide images of VSELs of the
quality required for reliable image processing, accurate masking
and feature calculations by Image Data Exploration and Analysis
Software (IDEAS). We have already performed such analyses in our
laboratory with a FlowSight demo instrument, and we could not
obtain reliable IDEAS data based on FlowSight acquisition, even
for human VSELs, which are much larger cells than their murine
counterparts (E Zuba-Surma, unpublished data). Therefore, and
importantly, the majority of small murine VSELs would not be
easily visible on a FlowSight instrument because of its limitations
in object resolution. This is also reflected by images in the paper
by Miyanishi et al.29 (original Figure S1C29 and shown as Figure 2d
in this article, left panel). FlowSight, with its standard optics pixel
resolution of 2 mm, which may be increased maximally to 1 mm/
pixel with the Quantitative Imaging Upgrade, still lacks sufficient
resolution for accurate VSEL size measurements.105 Based on our
extensive experience in VSEL size evaluation and imaging
cytometry, the following facts have become apparent: (1) the
only current imaging cytometer that is optically capable of
visualizing VSELs is the ImageStream system (both ImageStream
100 and ImageStream X systems, which were used in our VSEL
studies), (2) the quality of images of analyzed objects undermines
the accuracy of size measurements by IDEAS software for such
small objects as VSELs, which is related, for example, to accurate
masking set-up by the software, (3) the masking performed by
IDEAS should always be verified by the investigator and often fine-
tuned (for example, decreased), as the contribution of the cellular
halo is much more prominent for small objects than for larger
cells, significantly affecting the size calculation when masking
automatically based on the brightfield image.94–97,100,104
Unfortunately, the data on size measurements by imaging
cytometry provided by Miyanishi et al.29 do not in fact challenge
our previous results96 because: (1) these studies were not
performed with the high-resolution ImageStream system (our
major concern), (2) the quality of the images was poor compared
with the VSEL images used for initial calculations by Zuba-Surma
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et al.96 (Figure 2d) (major concern), (3) the CD45 /int/Lin /Sca-
1þ /Sytox16bri larger-cell population was analyzed excluding the
Sytox16dim fraction that resembled ‘VSEL candidates’ (major
concern), (4) no information was provided about the analytical
approach, including the type of masking or the features used for
size calculation, (5) a small number of objects was analyzed and (6)
the preparation of cells before analysis was different than in our
previously reported studies.29
Moreover, it would be very valuable to see all-channel images of
the only five small objects included in the analysis (original
Figure 2D in Miyanishi et al.29), which could give further ideas
about morphology and the potential similarity of these objects to
the previously described VSELs. On the other hand, the authors
showed only highly contrasted brightfield images of analyzed
cells.29 Most importantly, in our opinion, an incorrect population
was included in the analysis, and it would be much more valuable
to investigate CD45 /int/Lin /Sca-1þ /Sytox16dim cells based on
their full images, including all stained marker populations, to
evaluate both size and potential cell content for assessing the
VSEL presence in this fraction. Unfortunately, such an analysis will
be reliable only when performed on the more capable
ImageStream system.
However, even access to the high-quality ImageStream X
system does not guarantee good-quality images that would
provide accurate cell-size measurements, as was evident in the
study by Szade et al.,28 who failed to isolate VSELs. These authors
contradicted our reported results, whereas, in fact, the image
quality of objects used for their size measurements was very poor
(Figure S2 in Szade et al.28 and Figure 2d in this article, middle
panel). Furthermore, the population they focused on as VSELs
(CD45 /Lin /Sca-1þ /c-kitþ ) was not comparable to our reported
cells. On the other hand, the authors carelessly excluded
potentially crucial objects (4-5 mm in size based on their unknown
masking and diameter measurements) from size analysis in the
CD45 /Lin /Sca-1þ /c-kit fraction, which could contain VSELs
(Figure S2 in Szade et al.28 and Figure 2d in this article, middle
panel). Thus, such analysis, even performed on an ImageStream X
system, was not professionally performed, which underscores the
importance of a skilled and knowledgeable flow cytometry-skilled
operator who can fully understand and interpret data generated
by this state-of-the-art machine.
Importantly, the paper by Zuba-Surma et al.96 represents one of
the first studies in the stem cell research field that employed
imaging cytometry for identification and morphological
characterization of rare and small-sized stem cell objects, and all
calculations were performed in close collaboration with a scientific
representative of Amnis Corp. to ensure correct object
identification and data accuracy (as shown in example images
used in this study and shown in Figure 2d, right panel). Moreover,
it was the first paper that clearly showed that the fraction of
FSClow/SSClow/CD45 /Lin /Sca-1þ cells sorted by classical flow
cytometry (fluorescence-activated cell sorting) may not only
contain a great amount of debris and artifacts, but also include
small cellular objects such as VSELs.96 We further showed a similar
phenomenon, with even more debris because of enzymatic
digestion, for isolation of VSELs from solid tissues.95 It is
noteworthy that all of our previous VSEL size measurements
were performed with a  40 objective and a resolution of 0.5 mm
per pixel (on ImageStream 100 and ImageStream X systems,
Figure 2d, right panel).
Figure 3. Classical sorting strategy for murine BM-derived VSEL isolation by fluorescence-activated cell sorting (FACS). Agranular, small events
ranging from 2 to 10 mm (as initially set up with Flow Cytometry Size beads, Invitrogen/Molecular Probes) are included in an ‘extended
lymphgate’ on an FSC vs SSC dot plot (region R1; a). The population of cells from region R1 may be additionally depleted of doublets (gate R2;
b) to enhance sorting purity (b). The single-cell fraction from gate R2 is further analyzed for Sca-1 and Lin expression and exclusively Lin /
Sca-1þ cells are gated (R3) to avoid erythroblast contamination (c). The population from region R3 is subsequently separated into CD45 and
CD45þ subpopulations visualized in regions R4 and R5, respectively, on a CD45 vs SSC dot plot (d). CD45-dim objects are preferentially
included in the CD45þ population (region R5). If BM cells are gated strictly according to these steps (with special caution for R1, R3, R4 and R5
gate set-up), the populations of VSELs and HSCs derived from regions R4 and R5, respectively, separate cleanly when ‘back-gated’ on FSC vs
SSC dot plots (e). Both stem cell fractions may be additionally purified by final gating, including size-related regions R6 and R7 for VSEL and
HSC sorting, respectively. Percentages represent the content of each fraction in the representative murine BM sample.
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CONCLUSIONS
Murine BM-derived VSELs are very well described at the
morphological and molecular levels and express several morpho-
logical and molecular marks that support their pluripotent
character. In addition, evidence has accumulated that these cells
cross germ layers in their differentiation potential. The fact that
they do not form teratomas and do not complete blastocyst
development is well explained by changes in expression of certain
paternally imprinted genes. Is it really essential that a PSC should
show these properties? There should be scientific deliberation on
this—in fact this inability to form teratoma may prove to be a very
positive feature; such cells might be destined for regenerative
medicine. On the other hand, we have always emphasized that, in
contrast to their murine counterparts, much work still needs to be
done to better characterize human VSELs. Finally, we frankly
wonder why, faced with the difficulties of characterizing VSELs by
a handful of other groups,27–29 these groups have not openly, as is
usual in science, requested our help. The scientists are
wholeheartedly welcome to address themselves to us.
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